Inveready has started the year with a strong commitment to biotechnology. A few weeks ago we announced that it had invested in Oncostellae, and recently we have learned that it has invested in two more companies, in Ab-BIOTICS through its debt fund and in Cuantum through its Inveready Biotech II fund.
